Alphatec (NASDAQ:ATEC) Shares Break Above 200 Day Moving Average - Should You Sell?

Key Points

• Alphatec shares moved above their 200-day moving average, reaching $10.06 and last trading near $10.05, signaling improved technical momentum.
• Analysts remain broadly positive, with 13 Buy ratings out of 15 and a consensus price target of $17.40, despite some target-price revisions.
• The company reported 15.1% year-over-year revenue growth to $213.51 million and met earnings expectations, but remains unprofitable; CEO Patrick Miles also purchased 115,000 shares, while institutional investors own 66.35% of the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.56 and traded as high as $10.06. Alphatec shares last traded at $10.05, with a volume of 1,706,550 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ATEC shares. Stifel Nicolaus decreased their price objective on shares of Alphatec from $16.00 to $13.00 and set a "buy" rating on the stock in a report on Wednesday, July 8th. TD Cowen boosted their target price on shares of Alphatec from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. UBS Group upped their target price on shares of Alphatec from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Stephens assumed coverage on shares of Alphatec in a research note on Thursday, July 23rd. They set an "overweight" rating and a $15.00 price target on the stock. Finally, BMO Capital Markets raised their price target on shares of Alphatec from $11.00 to $12.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $17.40.

Alphatec Stock Down 0.7%

The firm's 50 day moving average price is $9.55 and its 200-day moving average price is $9.56. The company has a current ratio of 1.89, a quick ratio of 1.07 and a debt-to-equity ratio of 40.35. The company has a market cap of $1.55 billion, a P/E ratio of -14.15 and a beta of 0.85.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share for the quarter, hitting analysts' consensus estimates of $0.07. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The business had revenue of $213.51 million during the quarter, compared to the consensus estimate of $211.26 million. During the same period in the previous year, the firm posted $0.02 earnings per share. Alphatec's revenue for the quarter was up 15.1% compared to the same quarter last year. As a group, equities research analysts expect that Alphatec Holdings, Inc. will post -0.45 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Patrick Miles acquired 115,000 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The stock was acquired at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the completion of the acquisition, the chief executive officer owned 5,893,551 shares of the company's stock, valued at $51,922,184.31. This trade represents a 1.99% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, General Counsel Tyson Marshall sold 8,168 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total value of $78,821.20. Following the completion of the transaction, the general counsel directly owned 630,398 shares in the company, valued at $6,083,340.70. The trade was a 1.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 13.48% of the company's stock.

Institutional Trading of Alphatec

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Summit Securities Group LLC acquired a new stake in shares of Alphatec in the 1st quarter valued at approximately $29,000. Integrated Wealth Concepts LLC acquired a new position in Alphatec during the second quarter valued at approximately $52,000. Allworth Financial LP increased its stake in Alphatec by 82.6% in the second quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company's stock valued at $58,000 after purchasing an additional 3,015 shares in the last quarter. Lido Advisors LLC bought a new stake in Alphatec in the first quarter valued at approximately $115,000. Finally, Atlas Brown Inc. acquired a new stake in Alphatec in the second quarter worth $111,000. 66.35% of the stock is owned by institutional investors.

About Alphatec

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on improving the surgical treatment of spinal disorders. The company develops and commercializes products designed to support spine surgery, including implants, biologics, surgical instruments and related technologies.

Its portfolio is intended for procedures addressing conditions such as spinal deformities, degenerative disc disease and other disorders affecting the spine. Alphatec emphasizes surgeon-focused solutions and integrated technologies that support preoperative planning, intraoperative decision-making and the placement of spinal implants.

Headquartered in Carlsbad, California, Alphatec serves hospitals, surgeons and other healthcare providers in the United States and select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.